Cervical Microbiome Modulation for Radiation-Resistant HPV Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The impact of the microbiome on the response to radiation therapy for cervical cancer has not been well studied, and there is a need to understand the factors associated with tumor regression during chemoradiation treatment.
Innovation Solution
Treating subjects with an effective amount of an antibiotic and/or a probiotic to reduce the level of Lactobacillus inners, particularly in cervical mucosa samples, and administering probiotics that are free of Lactobacillus species, such as Prevotella, Bacteroides, and Porphyromonas, to enhance anti-tumor immunity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Lactobacillus inners are present in the cervical microbiome, then the microbiome composition is maintained, but the radiation response and tumor regression are suppressed
Solution Approach 1:
The patent extracts and removes Lactobacillus inners from the cervical microbiome using targeted antibiotics (such as clindamycin or metronidazole) before and during radiation therapy. This extraction eliminates the harmful factor that suppresses radiation response while preserving other beneficial microbiome components that promote tumor regression and immune activation.
Solution Approach 2:
The patent converts the harmful presence of Lactobacillus inners into a beneficial outcome by using antibiotic treatment to eliminate them, thereby transforming the microbiome composition to favor radiation response. The removal of this harmful species creates space for other beneficial bacteria to thrive and drive tumor regression.
2Reliability
If antibiotics are administered to reduce Lactobacillus inners, then radiation response is improved, but microbial diversity may be reduced
Solution Approach 1:
The patent applies local quality by using targeted antibiotics that specifically affect Lactobacillus inners while sparing other beneficial microbiome species. The treatment is localized to the cervical region and timed specifically before and during radiation therapy, allowing selective modification of the microbiome composition without globally disrupting diversity.
Solution Approach 2:
The patent implements preliminary action by administering antibiotics before radiation therapy to pre-establish a favorable microbiome composition. This preliminary modification ensures that the microbiome is optimized for radiation response before the treatment begins, while maintaining overall microbial diversity through selective targeting.
3Reliability
If probiotics containing Lactobacillus species are administered, then gut health is maintained, but anti-tumor immunity is suppressed
Solution Approach 1:
The patent applies the inversion principle by reversing the conventional approach of using Lactobacillus-containing probiotics. Instead, the patent uses probiotics that are specifically free of Lactobacillus species, such as those containing Bacteroides, Prevotella, or other beneficial non-Lactobacillus bacteria. This inverted approach maintains gut health while avoiding the suppression of anti-tumor immunity.
Data Source
AI summary
Provided herein are methods for identifying patient having treatment resistant cancers, such as HPV-related cancers. Therapeutic methods for treatment of cancers are also provided.